<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35489721</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1791-7530</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Anticancer research</Title>
          <ISOAbbreviation>Anticancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.</ArticleTitle>
        <Pagination>
          <StartPage>2327</StartPage>
          <EndPage>2340</EndPage>
          <MedlinePgn>2327-2340</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.15712</ELocationID>
        <Abstract>
          <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To characterize the growth pattern and antigen profile of peripheral nerve sheaths tumors (PNST) in a large series of tumors obtained from patients with neurofibromatosis type 1 (NF1).</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Tissue micro-array technique was applied to study 520 PNSTs of 385 patients with NF1 by immunohistochemistry for human epidermal growth factor receptors erb-b2 receptor tyrosine kinase 2 (ERBB2) and ERBB3, CD44, neuroregulin (NRG1) and proliferation index by Ki-67. PNSTs were classified as cutaneous neurofibroma (CNF) in 114 cases, diffuse neurofibroma (DNF) in 109, diffuse plexiform neurofibroma (DPNF) in 108, plexiform neurofibroma (PNF) in 110, and malignant PNST (MPNST) in 22.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The Ki-67 proliferation index was significantly higher in MPNST than in benign PNST (p&lt;0.001). ERBB2 expression was significantly lower in PNST with diffuse growth than in PNF and MPNST (p&lt;0.001). ERBB3 expression was also higher in PNF and MPNST (both p&lt;0.001) than in diffuse PNST. NRG1 expression was significantly higher in PNF than in non-encapsulated benign PNST or MPNST (both p&lt;0.001). Co-expression of ERBB2, ERBB3 and ligand NRG1 was rare, mainly observed in PNST with a plexiform component (in four PNFs, nine DPNFs, one CNF, and two MPNSTs). Expression of CD44 in contrast was significantly stronger in diffusely growing PNST than in PNF (p&lt;0.001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Growth factor receptors ERBB2 and ERBB3 were significantly up-regulated in PNF and MPNST. The antigen expression pattern of DPNF resembled that of benign PNST with diffuse growth pattern rather than that of encapsulated PNF. Differentiating PNST may be important for the assessment of neurofibroma progression, and for the expected impact of drugs currently used for tumor reduction.</AbstractText>
          <CopyrightInformation>Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Friedrich</LastName>
            <ForeName>Reinhard E</ForeName>
            <Initials>RE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Craniomaxillofacial Surgery, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany; rfriedrich@uke.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Nörnberg</LastName>
            <ForeName>Louisa K N</ForeName>
            <Initials>LKN</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Veterinary Pathology, Justus Liebig University Gießen, Gießen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hagel</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Anticancer Res</MedlineTA>
        <NlmUniqueID>8102988</NlmUniqueID>
        <ISSNLinking>0250-7005</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018960">Hyaluronan Receptors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017978">Receptors, Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C581292">ERBB3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018960" MajorTopicYN="N">Hyaluronan Receptors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018317" MajorTopicYN="Y">Nerve Sheath Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009455" MajorTopicYN="Y">Neurofibroma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018318" MajorTopicYN="Y">Neurofibroma, Plexiform</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="Y">Neurofibrosarcoma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010524" MajorTopicYN="Y">Peripheral Nervous System Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017978" MajorTopicYN="N">Receptors, Growth Factor</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ERBB2</Keyword>
        <Keyword MajorTopicYN="N">ERBB3</Keyword>
        <Keyword MajorTopicYN="N">Ki-67</Keyword>
        <Keyword MajorTopicYN="N">NRG1</Keyword>
        <Keyword MajorTopicYN="N">Neurofibromatosis type 1</Keyword>
        <Keyword MajorTopicYN="N">diffuse plexiform neurofibroma</Keyword>
        <Keyword MajorTopicYN="N">malignant peripheral nerve sheath tumor</Keyword>
        <Keyword MajorTopicYN="N">neurofibroma</Keyword>
        <Keyword MajorTopicYN="N">neurofibroma classification</Keyword>
        <Keyword MajorTopicYN="N">plexiform neurofibroma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35489721</ArticleId>
        <ArticleId IdType="doi">10.21873/anticanres.15712</ArticleId>
        <ArticleId IdType="pii">42/5/2327</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
